(Q45450156)

14 December 2017

title

Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses (English)

1 reference

14 December 2017

Carlo Zanotto

1

1 reference

14 December 2017

Manuela Paganini

2

1 reference

14 December 2017

Veronica Elli

3

1 reference

14 December 2017

Valeria Basavecchia

4

1 reference

14 December 2017

Margherita Neri

5

1 reference

14 December 2017

Carlo De Giuli Morghen

6

1 reference

14 December 2017

Antonia Radaelli

7

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

14 December 2017

1 reference

14 December 2017

volume

23

1 reference

14 December 2017

issue

39

1 reference

14 December 2017

page(s)

4745-4753

1 reference

The past, present and future of HIV-vaccine development: a critical view.

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Vaccines for the prevention of HIV-1 disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Expression of HIV-1 envelope gene by recombinant avipox viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV inf

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Production of Immunogenic HIV-1 Viruslike Particles in Stably Engineered Monkey Cell Lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Production and characterization of simian--human immunodeficiency virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Production of non-infectious human immunodeficiency virus-like particles which package specifically viral RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Formation of Lentivirus Particles by Mammalian Cells Infected with Recombinant Fowlpox Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Immunization with lentivirus-like particles elicits a potent SIV-specific recall cytotoxic T-lymphocyte response in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Time course of Gag protein assembly in HIV-1-infected cells: a study by immunoelectron microscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Biochemical analysis of the N-glycosylation pathway in baculovirus-infected lepidopteran insect cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

The Simian Immunodeficiency Virus 5′ Untranslated Leader Sequence Plays a Role in Intracellular Viral Protein Accumulation and in RNA Packaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

MHC-I-restricted presentation of HIV-1 virion antigens without viral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

T- and B-lymphocyte responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/hepatitis B surface antigen particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.05.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.05.003

1 reference

14 December 2017

1 reference